City of Hope’s median survival surpasses SEER LA in Stages I–IV Prostate Cancer*
The Prostate Cancer Program at City of Hope — providing optimal outcomes in prostate cancer

As a founding member of the National Comprehensive Cancer Network, our doctors help develop and improve evidence-based prostate cancer treatment guidelines for patients throughout the country. Our prostate cancer program treats nearly 6,000 patients, a year and our five-year survival rate is very close to 100 percent. City of Hope is home to one of California’s largest prostate cancer programs and maintains one of the largest databases of prostate cancer outcomes.*

Customized care is offered from a close interdisciplinary team of the best oncologists, radiation oncologists, surgical oncologists and researchers, who work with prostate cancer patients to develop an individualized treatment plan based on their unique genomic, psychosocial and cultural needs.

Providing a comprehensive team of healthcare professionals in one central place

The proximity of our broad interdisciplinary team makes collaboration and access convenient for clinicians and patients. Our prostate cancer program staff includes:

- Oncologists
- Radiation oncologists
- Surgical oncologists
- Urologists
- Researchers
- Psychologists
- Psychiatrists
- Nurses
- Social workers
- Chaplains

Why We Measure Outcomes

We measure outcomes to challenge ourselves to continually improve quality of care, give clinicians a measure of our performance, demonstrate value to payers and give patients confidence.

*Office of Statewide Health Planning and Development.
Data were derived from the City of Hope Cancer Registry (CNeXT) and SEER December 2017 Disease Specific Data Files, with the Los Angeles Registry as the comparator. All patients were diagnosed from 2005 through 2014, and the City of Hope follow-up cutoff date was 12/31/2015, to align with SEER data.

The National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program

An authoritative source on cancer incidence and survival, the SEER Program provides cancer statistics to reduce the cancer burden among the U.S. population. It is supported by the Surveillance Research Program, which provides national leadership in cancer surveillance using analytical tools and methodological expertise in collecting, analyzing, interpreting and disseminating reliable population-based statistics.
Minimally invasive robotically assisted prostatectomies

- We are leaders in minimally invasive, robotically assisted prostatectomies, having performed more than 8,000 procedures.
- These procedures are nerve-sparing, reducing discomfort and recovery time while preserving urinary and sexual function.

Ultrasound ablation

- For patients who do not wish to “watch and wait,” our surgeons were the first in the nation to perform ultrasound ablation of prostate cancer cells guided precisely to the target by magnetic resonance imaging (MRI).
- This technique provides focal therapy with a much lower risk profile than standard invasive therapy.

Clinical Cancer Genetics, Cancer Screening & Prevention Program™

- City of Hope’s Division of Clinical Cancer Genomics’ Cancer Screening & Prevention Program™ offers a comprehensive cancer risk assessment to determine a patient’s risk of carrying a mutation that predisposes them to cancer.
- If a mutation is suspected, genetic counselors explain the risks and benefits of genetic testing, recommend strategies to lower the risk of developing cancer, and explain the implications of results to the patient and his or her family.

Helical TomoTherapy

- Delivers radiation therapy with surgical precision, reducing risk to normal tissue.

MRI-guided focused ultrasound

- Uses MRI to detail images of the prostate, followed by highly focused ultrasound to heat and destroy cancerous tissue.

Brachytherapy options

- Depending on the extent of the disease, we offer a range of patient health and treatment goals.

On-site assistance to help patients before and after their procedure

- Biopsychosocial screening: A tablet-based, touch-screen tool or “electronic confidante” developed by City of Hope asks all patients a wide range of questions relating to physical and psychosocial concerns common to their diagnosis — once identified, the appropriate healthcare professional addresses their concerns.
- A dedicated continence recovery program: To help men regain urinary function after treatment is available, as needed.
- Specific drug treatments for conditions related to prostate cancer such as sexual dysfunction and bone loss due to metastasis are offered.

“City of Hope is a pioneer in robotic surgery ... we were doing it before anyone else and have taught surgeons nationwide ... from straightforward to complex cases.”

— Clayton Lau, M.D.
Providing innovative, on-site and ongoing research and clinical trials

City of Hope has a “bench to bedside” approach that is unlike any other cancer center. The staff at the Prostate Cancer Program has the opportunity to conduct leading-edge research and enroll patients in clinical trials that may be life-prolonging and even lifesaving. These translational R&D efforts quickly allow innovative, customized treatments to be available to our patients.

Our innovative research is focused on the early diagnosis and prevention of prostate cancer, intraoperative imaging, prostate cancer disparities, identification of high-risk prostate cancer patients and quality-of-life issues involving prostate cancer treatment.

City of Hope currently conducts more than 500 clinical trials, enrolling more than 6,200 patients.

Our current prostate cancer investigations include:

- Anticipated to open in November 2018, we are exploring CAR T cell therapy for prostate cancer, including targets that will kill adenocarcinoma (with PSCA), as well as neuroendocrine small cell disease (with CEACAM5).
- We are participating in a study assessing the efficacy and safety of talazoparib (poly ADP ribose polymerase inhibitor) in men with DNA repair defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy and progressed on at least one novel hormonal agent.
- Additionally, we are looking at a study that will evaluate the safety and efficacy of atezolizumab (anti-PD-L1 antibody) in combination with sipuleucel-T in participants with mCRPC after failure of an androgen synthesis inhibitor (e.g., abiraterone).
- A randomized phase III trial is being conducted to evaluate the efficacy, safety and pharmacokinetics of ipatasertib vs placebo (both combined with abiraterone and prednisone/prednisolone) in patients with previously untreated mCRPC.
- A current recruiting trial involves focal MR-guided focused ultrasound treatment of localized intermediate-risk prostate lesions.
- A phase II study is being conducted to determine how effective radium Ra 223 dichloride, hormone therapy and stereotactic body radiation are in treating patients with prostate cancer that has spread to other places in the body.
- A randomized phase II trial is being conducted to evaluate the impact of cytoreductive radical prostatectomy combined with best systemic therapy on oncologic and quality-of-life outcomes in men with newly diagnosed metastatic prostate cancer.
- A genetic epidemiology study on modifiers of vitamin D levels and risk for prostate cancer in diverse populations.
- A study on the anti-cancer benefits of vitamin D, its mechanistic role and specifically vitamin D signaling and its role in immune surveillance in the prostate.
- A long-standing study on the interrogation of genetic variations to determine prostate cancer susceptibility genes and new biomarkers.
- We are studying the issue of overuse or underuse of prostate cancer interventions from the perspective of rational choice theory, as well as the role of emotions in medical decision-making for older adults with prostate cancer.
Our customized Survivorship Program — helping patients improve their quality of life

At City of Hope, we strive to “maximize the wellness for all people affected by cancer.” This includes not only patient survivors, from the time of diagnosis throughout the balance of their life, but also their family and caregivers.

Our Survivorship Program, a long-term follow-up program, helps patients deal with the long-term complications of treatment and focus on novel approaches to improve long-term quality of life. We offer specialized patient follow-up care and education in a clinical research setting. By participating in research, our patients help us learn more about issues facing cancer survivors and provide opportunities to continually improve survivorship care for our patients and for the medical community at large.

Our Survivorship Program provides short- and long-term follow-up with patients and their families to:

- Immediately address postsurgical complications
- Manage toxicities
- Assist in early detection of recurrence
- Provide psychosocial support
- Identify other areas where intervention may be needed

“I felt I was better off in a City of Hope environment, where it’s a cancer treatment specialty hospital. This is what they do.”

— Ralph Richardson, prostate cancer patient
Meet the leaders of our prostate cancer program

Tanya Dorff, M.D.

- Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
- Medical Oncologist

Clayton S. Lau, M.D.

- Pauline & Martin Collins Family Chair in Urology
- Chief, Division of Urology and Urologic Oncology
- Director, Urologic Oncology and Robotic Surgery Fellowship
- Director, Prostate Cancer Program
- Head, Retroperitoneal Surgery
- Associate Clinical Professor, Department of Surgery
- Surgeon

“Our scientists at City of Hope are really thinking of new, innovative ways to treat cancer; not just incremental advances, but potentially game changing therapies. There’s also a huge focus on immunotherapy, which I’ve always believed is the way to treat cancer — the way of the future.”

— Tanya Dorff, M.D.
About City of Hope

City of Hope is a leading research, treatment and education center with a multidisciplinary, interactive approach to developing and testing new therapies, while delivering holistic care to patients and their families. With a 105-year legacy, we are achieving superior outcomes by bringing together the best and the brightest clinicians and medical researchers who possess vision, passion, integrity, state-of-the-art knowledge and compassion. We provide these dedicated experts with an environment where interdisciplinary collaboration is an expected constant, and where together they can provide the best, most appropriate interventions for each patient.

Designated one of only 49 comprehensive cancer centers, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance cancer care throughout the world.

To find out more about City of Hope’s prostate cancer program, visit CityofHope.org/clinical-program/prostate-cancer.

To begin the referral process for your patients with prostate cancer:

- Call 800-COH-4DRS (264-4377), Monday through Friday, 8 a.m. to 6 p.m., to speak with a patient referral specialist.
- Fax a referral request letter with a patient fact sheet to 626-301-8432.
- Complete an online referral request form at CityofHope.org/refer-a-patient.
- Visit clinicaltrials.coh.org or call 626-218-1133 to see if one of our clinical trials holds promise for your patients.